About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Molecular Profiling Protocol (SCRI-CA-001)

NCT00530192·9 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Scottsdale Healthcare

With

Translational Genomics Research Institute

Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Metastatic cancer which has progressed on 2 prior chemotherapeutic, hormonal or biological regimens for advanced disease.
Be defined as refractory to the last line of therapy
Have documentation of the best clinical response to the treatment regimen immediately prior to entering this study

You may not be if

Patients with symptomatic CNS metastasis
Any previous history of another malignancy within 5 years of study entry
Uncontrolled intercurrent illness
Known HIV, HBV, HCV infection
Pregnant or breast-feeding

The record

StatusCompleted

PhaseEarly phase 1

Taking part86

StartedSep 2006

UpdatedJul 10, 2009

Conditions

Refractory Cancer

Where9

Oncology Specialties
Huntsville, Alabama, United States
TGen Clinical Research Services
Scottsdale, Arizona, United States
Mayo Clinic
Scottsdale, Arizona, United States

Clareo Health | Molecular Profiling Protocol (SCRI-CA-001)